| Autor: |
Niikura N; Dept. of Surgery, Sougo Oota Hospital, Japan., Kimura M, Kobayashi Y, Asahara F, Hayashi K, Shibata S, Shintoku J |
| Jazyk: |
japonština |
| Zdroj: |
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2009 Jun; Vol. 36 (6), pp. 1013-6. |
| Abstrakt: |
The efficacy of aromatase inhibitors(AI)has been established for adjuvant and metastatic breast cancer. However, decision making regarding treatment becomes difficult after AI treatment. Recently, high-dose toremifene(HD-TOR, TOR 120 mg daily)showed efficacy in these patients. We attempted to study retrospectively the efficacy and safety of HD-TOR treatment. Seven patients received HD-TOR. The overall response rate was 29%(PR 2)and clinical benefit (CR, PR, long SD)was 57%(PR 2, long SD 7). HD-TOR may be an optional treatment for MBC after AI treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
